A Single Arm Phase II Trial of Sintilimab and Bevacizumab Biosimilar Combined With PLD in Pretreated mTNBC
Status:
Recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of sintilimab and bevacizumab biosimilar combined with
pegylated liposomal doxorubicin in pretreated metastatic triple-negative breast cancer